Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Biochemistry ; 57(5): 827-838, 2018 Feb 06.
Artículo en Inglés | MEDLINE | ID: mdl-29278326

RESUMEN

Deleterious mutations in the serine lipase DDHD2 are a causative basis of complex hereditary spastic paraplegia (HSP, subtype SPG54) in humans. We recently found that DDHD2 is a principal triglyceride hydrolase in the central nervous system (CNS) and that genetic deletion of this enzyme in mice leads to ectopic lipid droplet (LD) accumulation in neurons throughout the brain. Nonetheless, how HSP-related mutations in DDHD2 relate to triglyceride metabolism and LD formation remains poorly understood. Here, we have characterized a set of HSP-related mutations in DDHD2 and found that they disrupt triglyceride hydrolase activity in vitro and impair the capacity of DDHD2 to protect cells from LD accumulation following exposure to free fatty acid, an outcome that was also observed with a DDHD2-selective inhibitor. We furthermore isolated and characterized LDs from brain tissue of DDHD2-/- mice, revealing that they contain both established LD-associated proteins identified previously in other organs and CNS-enriched proteins, including several proteins with genetic links to human neurological disease. These data, taken together, indicate that the genetic inactivation of DDHD2, as caused by HSP-associated mutations, substantially perturbs lipid homeostasis and the formation and content of LDs, underscoring the importance of triglyceride metabolism for normal CNS function and the key role that DDHD2 plays in this process.


Asunto(s)
Proteínas Asociadas a Gotas Lipídicas/análisis , Gotas Lipídicas/química , Proteínas del Tejido Nervioso/fisiología , Fosfolipasas/fisiología , Animales , Química Encefálica , Dominio Catalítico/efectos de los fármacos , Ácidos Grasos/metabolismo , Homeostasis , Humanos , Ratones , Ratones Noqueados , Microscopía Confocal , Mutagénesis Sitio-Dirigida , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Proteínas del Tejido Nervioso/genética , Especificidad de Órganos , Fosfolipasas/antagonistas & inhibidores , Fosfolipasas/genética , Fosfolipasas A1/deficiencia , Proteínas Recombinantes/metabolismo , Paraplejía Espástica Hereditaria/genética , Triglicéridos/metabolismo
2.
Proc Natl Acad Sci U S A ; 111(41): 14924-9, 2014 Oct 14.
Artículo en Inglés | MEDLINE | ID: mdl-25267624

RESUMEN

Complex hereditary spastic paraplegia (HSP) is a genetic disorder that causes lower limb spasticity and weakness and intellectual disability. Deleterious mutations in the poorly characterized serine hydrolase DDHD2 are a causative basis for recessive complex HSP. DDHD2 exhibits phospholipase activity in vitro, but its endogenous substrates and biochemical functions remain unknown. Here, we report the development of DDHD2(-/-) mice and a selective, in vivo-active DDHD2 inhibitor and their use in combination with mass spectrometry-based lipidomics to discover that DDHD2 regulates brain triglycerides (triacylglycerols, or TAGs). DDHD2(-/-) mice show age-dependent TAG elevations in the central nervous system, but not in several peripheral tissues. Large lipid droplets accumulated in DDHD2(-/-) brains and were localized primarily to the intracellular compartments of neurons. These metabolic changes were accompanied by impairments in motor and cognitive function. Recombinant DDHD2 displays TAG hydrolase activity, and TAGs accumulated in the brains of wild-type mice treated subchronically with a selective DDHD2 inhibitor. These findings, taken together, indicate that the central nervous system possesses a specialized pathway for metabolizing TAGs, disruption of which leads to massive lipid accumulation in neurons and complex HSP syndrome.


Asunto(s)
Lipasa/metabolismo , Fosfolipasas A1/metabolismo , Paraplejía Espástica Hereditaria/enzimología , Animales , Encéfalo/metabolismo , Encéfalo/ultraestructura , Cognición , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Eliminación de Gen , Marcación de Gen , Células HEK293 , Humanos , Lipasa/antagonistas & inhibidores , Gotas Lipídicas/metabolismo , Gotas Lipídicas/ultraestructura , Locomoción , Ratones Endogámicos C57BL , Neuronas/metabolismo , Fosfolipasas , Fosfolipasas A1/antagonistas & inhibidores , Fosfolipasas A1/deficiencia , Reproducibilidad de los Resultados , Paraplejía Espástica Hereditaria/genética , Triglicéridos/metabolismo
3.
Cell Death Dis ; 9(8): 797, 2018 07 23.
Artículo en Inglés | MEDLINE | ID: mdl-30038238

RESUMEN

DDHD2/KIAA0725p is a mammalian intracellular phospholipase A1 that exhibits phospholipase and lipase activities. Mutation of the DDHD2 gene causes hereditary spastic paraplegia (SPG54), an inherited neurological disorder characterized by lower limb spasticity and weakness. Although previous studies demonstrated lipid droplet accumulation in the brains of SPG54 patients and DDHD2 knockout mice, the cause of SPG54 remains elusive. Here, we show that ablation of DDHD2 in mice induces age-dependent apoptosis of motor neurons in the spinal cord. In vitro, motor neurons and embryonic fibroblasts from DDHD2 knockout mice fail to survive and are susceptible to apoptotic stimuli. Chemical and probe-based analysis revealed a substantial decrease in cardiolipin content and an increase in reactive oxygen species generation in DDHD2 knockout cells. Reactive oxygen species production in DDHD2 knockout cells was reversed by the expression of wild-type DDHD2, but not by an active-site DDHD2 mutant, DDHD2 mutants related to hereditary spastic paraplegia, or DDHD1, another member of the intracellular phospholipase A1 family whose mutation also causes spastic paraplegia (SPG28). Our results demonstrate the protective role of DDHD2 for mitochondrial integrity and provide a clue to the pathogenic mechanism of SPG54.


Asunto(s)
Apoptosis , Fosfolipasas A1/genética , Especies Reactivas de Oxígeno/metabolismo , Paraplejía Espástica Hereditaria/patología , Adenosina Trifosfato/metabolismo , Animales , Apoptosis/efectos de los fármacos , Cardiolipinas/metabolismo , Células Cultivadas , Modelos Animales de Enfermedad , Fibroblastos/citología , Fibroblastos/metabolismo , Humanos , Ratones , Ratones Noqueados , Mitocondrias/metabolismo , Neuronas Motoras/citología , Neuronas Motoras/metabolismo , Fosfolipasas , Fosfolipasas A1/deficiencia , Paraplejía Espástica Hereditaria/genética , Médula Espinal/metabolismo , Médula Espinal/patología , Estaurosporina/farmacología
4.
FEBS Lett ; 584(21): 4389-95, 2010 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-20932832

RESUMEN

Mammals have three members of the intracellular phospholipase A(1) protein family (phosphatidic acid preferring-phospholipase A(1), p125, and KIAA0725p). In this study, we showed that KIAA0725p is localized in the Golgi, and is rapidly cycled between the Golgi and cytosol. Catalytic activity is important for targeting of KIAA0725p to Golgi membranes. RNA interference experiments suggested that KIAA0725p contributes to efficient membrane trafficking from the Golgi apparatus to the plasma membrane, but is not involved in brefeldin A-induced Golgi-to-endoplasmic reticulum retrograde transport.


Asunto(s)
Membrana Celular/metabolismo , Aparato de Golgi/metabolismo , Fosfolipasas A1/metabolismo , Animales , Biocatálisis , Brefeldino A/farmacología , Citosol/metabolismo , Retículo Endoplásmico/efectos de los fármacos , Retículo Endoplásmico/metabolismo , Técnicas de Silenciamiento del Gen , Células HeLa , Humanos , N-Acetil-Lactosamina Sintasa/metabolismo , Fosfolipasas A1/deficiencia , Fosfolipasas A1/genética , Transporte de Proteínas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda